{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:38:47Z","timestamp":1758587927434,"version":"3.44.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.therap.2018.09.073","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T03:01:07Z","timestamp":1540522867000},"page":"199-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The systematic case-referent method"],"prefix":"10.1016","volume":"74","author":[{"given":"Lamiae","family":"Grimaldi-Bensouda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucien","family":"Abenhaim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.therap.2018.09.073_bib0300","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s002280050382","article-title":"European network for the case-population surveillance of rare diseases (Euronet). A prospective feasibility study","volume":"53","author":"Capell\u00e0","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"9\u201310","key":"10.1016\/j.therap.2018.09.073_bib0305","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s002280000190","article-title":"Agranulocytosis associated with calcium dobesilate clinical course and risk estimation with the case-control and the case-population approaches","volume":"56","author":"Ib\u00e1\u00f1ez","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.therap.2018.09.073_bib0310","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/jnci\/djk003","article-title":"Statin use and risk of colorectal cancer","volume":"99","author":"Coogan","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.therap.2018.09.073_bib0315","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/pds.1970","article-title":"Statin and NSAID use and prostate cancer risk","volume":"19","author":"Coogan","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"24","key":"10.1016\/j.therap.2018.09.073_bib0320","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.therap.2018.09.073_bib0325","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00228-015-1810-6","article-title":"Flupirtine-induced liver injury- seven cases from the Berlin Case-Control Surveillance Study and review of the German spontaneous adverse drug reaction-reporting database","volume":"71","author":"Douros","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.09.073_bib0330","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/oxfordjournals.aje.a112220","article-title":"Estimability and estimation in case-referent studies","volume":"103","author":"Miettinen","year":"1976","journal-title":"Am J Epidemiol"},{"issue":"22","key":"10.1016\/j.therap.2018.09.073_bib0335","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1136\/hrt.2011.222448","article-title":"Risk of ST versus non-ST elevation myocardial infarction associated with non-steroidal anti-inflammatory drugs","volume":"97","author":"Grimaldi-Bensouda","year":"2011","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.therap.2018.09.073_bib0340","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ijcard.2013.08.127","article-title":"Real-life effectiveness of statins in the prevention of first acute coronary syndrome in France: a prospective observational study","volume":"169","author":"Grimaldi-Bensouda","year":"2013","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.therap.2018.09.073_bib0345","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/annrheumdis-2012-202972","article-title":"Impact of allopurinol on risk of myocardial infarction","volume":"74","author":"Grimaldi-Bensouda","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"10.1016\/j.therap.2018.09.073_bib0350","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/heartjnl-2017-312534","article-title":"Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction","volume":"104","author":"Grimaldi-Bensouda","year":"2018","journal-title":"Heart"},{"issue":"S2","key":"10.1016\/j.therap.2018.09.073_bib0355","article-title":"Non-valvular atrial fibrillation, VKA and non-VKA anticoagulants and stroke: the stroke prevention and anticoagulants (SPA) case-control study. International Conference of Pharmacoepidemiology","volume":"26","author":"Grimaldi-Bensouda","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"S2","key":"10.1016\/j.therap.2018.09.073_bib0360","first-page":"3","article-title":"Comparative patterns of use of non-vitamin K antagonist oral anticoagulants and risk of haemorrhage in real life. The Stroke Prevention and Anticoagulants study","volume":"26","author":"Grimaldi-Bensouda","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.therap.2018.09.073_bib0365","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/art.38429","article-title":"The risk of systemic lupus erythematosus associated with vaccines: an international case-control study","volume":"66","author":"Grimaldi-Bensouda","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.therap.2018.09.073_bib0370","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaut.2017.01.005","article-title":"Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: six years of case-referent surveillance","volume":"79","author":"Grimaldi-Bensouda","year":"2017","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.therap.2018.09.073_bib0375","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/joim.12155","article-title":"Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects","volume":"275","author":"Grimaldi-Bensouda","year":"2014","journal-title":"J Intern Med"},{"issue":"25","key":"10.1016\/j.therap.2018.09.073_bib0380","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1182\/blood-2012-05-431098","article-title":"A case-control study to assess the risk of immune thrombocytopenia associated with vaccines","volume":"120","author":"Grimaldi-Bensouda","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.therap.2018.09.073_bib0385","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3324\/haematol.2016.146373","article-title":"Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome","volume":"101","author":"Grimaldi-Bensouda","year":"2016","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.therap.2018.09.073_bib0390","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26389","article-title":"Childhood immune thrombocytopenia: a nationwide cohort study on condition management and outcomes","volume":"64","author":"Grimaldi-Bensouda","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.therap.2018.09.073_bib0395","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/aje\/kwr072","article-title":"Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A\/H1N1 viruses","volume":"174","author":"Grimaldi-Bensouda","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.therap.2018.09.073_bib0400","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijcard.2018.04.007","article-title":"Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study","volume":"266","author":"Grimaldi-Bensouda","year":"2018","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.therap.2018.09.073_bib0405","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2337\/dc13-0695","article-title":"Risk of breast cancer by individual insulin use: an international multicenter study","volume":"37","author":"Grimaldi-Bensouda","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.therap.2018.09.073_bib0410","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/pds.4160","article-title":"Antiepileptic drugs and risk of suicide attempts: a case-control study exploring the impact of underlying medical conditions","volume":"26","author":"Grimaldi-Bensouda","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.therap.2018.09.073_bib0415","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/sim.4780050605","article-title":"Adjustment of risk ratios in case-base studies (hybrid epidemiologic designs)","volume":"5","author":"Greenland","year":"1986","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.therap.2018.09.073_bib0420","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/oxfordjournals.aje.a114759","article-title":"External comparisons with the case-cohort design","volume":"126","author":"Wacholder","year":"1987","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.therap.2018.09.073_bib0425","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0895-4356(89)90037-1","article-title":"Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions","volume":"42","author":"Miettinen","year":"1989","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"10.1016\/j.therap.2018.09.073_bib0430","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group","volume":"335","author":"Abenhaim","year":"1996","journal-title":"N Engl J Med"},{"issue":"9304","key":"10.1016\/j.therap.2018.09.073_bib0435","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(02)07605-5","article-title":"Case-control studies: research in reverse","volume":"359","author":"Schulz","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.therap.2018.09.073_bib0440","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/pds.3401","article-title":"Agreement between patients\u2019 self-report and medical records for vaccination: the PGRx database","volume":"22","author":"Grimaldi-Bensouda","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.therap.2018.09.073_bib0445","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/pds.3194","article-title":"Agreement between patients\u2019 self-report and physicians\u2019 prescriptions on nonsteroidal anti-inflammatory drugs and other drugs used in musculoskeletal disorders: the international Pharmacoepidemiologic General Research eXtension database","volume":"21","author":"Grimaldi-Bensouda","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.therap.2018.09.073_bib0450","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/pds.1952","article-title":"Agreement between patients\u2019 self-report and physicians\u2019 prescriptions on cardiovascular drug exposure: the PGRx database experience","volume":"19","author":"Grimaldi-Bensouda","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.therap.2018.09.073_bib0455","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/sj.bjc.6690651","article-title":"Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing","volume":"81","author":"Collet","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.therap.2018.09.073_bib0460","unstructured":"Grimaldi-Bensouda L. \u00c9valuation et application d\u2019une nouvelle m\u00e9thode syst\u00e9matique cas-r\u00e9f\u00e9rents en pharmaco-\u00e9pid\u00e9miologie. Etudes dans l\u2019infarctus du myocarde. Th\u00e8se d\u2019universit\u00e9. https:\/\/www.theses.fr\/2009TOUR3136. [Accessed 19 October 2018]."},{"key":"10.1016\/j.therap.2018.09.073_bib0465","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/pds.3593","article-title":"Post-licensure safety surveillance for human papillomavirus-16\/18-AS04-adjuvanted vaccine: more than 4 years of experience","volume":"23","author":"Angelo","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2018.09.073_bib0470","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s10067-014-2846-1","article-title":"A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events","volume":"34","author":"Geier","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.therap.2018.09.073_bib0475","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jama.2014.16946","article-title":"Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system","volume":"313","author":"Scheller","year":"2015","journal-title":"JAMA"},{"issue":"36","key":"10.1016\/j.therap.2018.09.073_bib0480","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.vaccine.2017.06.030","article-title":"Human papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2 million young girls in France","volume":"35","author":"Miranda","year":"2017","journal-title":"Vaccine"},{"year":"1978","series-title":"The swine flu affair: decision-making on a slippery disease","author":"Neustadt","key":"10.1016\/j.therap.2018.09.073_bib0485"},{"key":"10.1016\/j.therap.2018.09.073_bib0490","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d3908","article-title":"Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe","volume":"343","author":"Dieleman","year":"2011","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.therap.2018.09.073_bib0495","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1473-3099(13)70104-X","article-title":"Risk of Guillain-Barr\u00e9 syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study","volume":"13","author":"Kwong","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.therap.2018.09.073_bib0500","doi-asserted-by":"crossref","first-page":"417e23","DOI":"10.1056\/NEJM198608143150703","article-title":"Coronary arteriographic findings soon after non-Q-wave myocardial infarction","volume":"315","author":"DeWood","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2018.09.073_bib0505","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJM198010163031601","article-title":"Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction","volume":"303","author":"DeWood","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2018.09.073_bib0510","first-page":"879e90","article-title":"COX-2 and beyond: approaches to prostaglandin inhibition in human disease","volume":"2","author":"FitzGerald","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.therap.2018.09.073_bib0515","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/CRD.0b013e318229a908","article-title":"Allopurinol as a cardiovascular drug","volume":"19","author":"Kelkar","year":"2011","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.therap.2018.09.073_bib0520","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2018.09.073_bib0525","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"9743","key":"10.1016\/j.therap.2018.09.073_bib0530","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(10)61374-8","article-title":"The international study of insulin and cancer","volume":"376","author":"Grimaldi-Bensouda","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.therap.2018.09.073_bib0535","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","article-title":"The influence of glucose-lowering therapies on cancer risk in type 2 diabetes","volume":"52","author":"Currie","year":"2009","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.therap.2018.09.073_bib0540","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1007\/s00125-009-1418-4","article-title":"Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study","volume":"52","author":"Hemkens","year":"2009","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.therap.2018.09.073_bib0545","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00125-009-1444-2","article-title":"Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden","volume":"52","author":"Jonasson","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.therap.2018.09.073_bib0550","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00125-009-1453-1","article-title":"Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group","volume":"52","author":"Colhoun","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.therap.2018.09.073_bib0555","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0140-6736(09)61307-6","article-title":"Insulin glargine and malignancy: an unwarranted alarm","volume":"374","author":"Pocock","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2018.09.073_bib0560","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(09)61477-X","article-title":"Insulin glargine and cancer: another side to the story?","volume":"374","author":"Gale","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2018.09.073_bib0565","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1089\/dia.2009.1705","article-title":"Insulin glargine and cancer\u2013an unsubstantiated allegation","volume":"11","author":"Garg","year":"2009","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.therap.2018.09.073_bib0570","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s00125-010-1675-2","article-title":"Diabetes therapy and cancer risk: causal effects and other plausible explanations","volume":"53","author":"Hernandez-D\u0131az","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.therap.2018.09.073_bib0575","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00125-009-1441-5","article-title":"Does diabetes therapy influence the risk of cancer?","volume":"52","author":"Smith","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.therap.2018.09.073_bib0580","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.2337\/dc13-0263","article-title":"Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin","volume":"36","author":"Sturmer","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.therap.2018.09.073_bib0585","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.2337\/dc13-0140","article-title":"Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes","volume":"36","author":"Habel","year":"2013","journal-title":"Diabetes Care"},{"issue":"S2","key":"10.1016\/j.therap.2018.09.073_bib0590","article-title":"Risk of stroke and myocardial infarction in users of vasoconstrictor drugs for ear, nose and throat-related conditions","volume":"26","author":"Grimaldi-Bensouda","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595718302415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595718302415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:53:56Z","timestamp":1758567236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595718302415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0040595718302415"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2018.09.073","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The systematic case-referent method","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2018.09.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}